MSCsPP also exhibited better effects than MSCsBM in term of improving the histological scores (1.30 ± 0.45 vs. 2.20 ± 0.67, p < 0.05, Figure 2E) and reducing the MPO activity (7571.32 ± 156.85 vs. 8661.37 ± 619.28 pg/ml, p < 0.001) and inflammatory cytokine levels (Figure 2F), including IFN‐γ (13.49 ± 1.22 vs. 22.02 ± 1.74 ng/ml, p < 0.05), TNF‐α (1.93 ± 0.18 vs. 3.27 ± 0.89 ng/ml, p < 0.01) and IL‐17 (103.95 ± 23.75 vs. 160.78 ± 10.29 pg/ml, p < 0.01), in local IBD lesions. This evidence concerns the gene MPO and inflammatory bowel disease.